Viruses evolve, and vaccines should too. That was the big-picture takeaway from a pivotal meeting this week of the FDA’s expert advisory panel. The question before them was simple: Ahead of an expected winter surge, should vaccine manufacturers tweak their forthcoming booster shots to target Omicron, or should they stick with the tried-and-true 2020 recipe?